UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus

American journal of health-system pharmacy, 2005-01, Vol.62 (2), p.173-181

2005

Volltextzugriff (PDF)

Tumor Targeting and Lipid Rafts Disrupting Hyaluronic Acid-Cyclodextrin-Based Nanoassembled Structure for Cancer Therapy

ACS applied materials & interfaces, 2018-10, Vol.10 (43), p.36628-36640

2018

Volltextzugriff (PDF)

Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes

Diabetes care, 2005-05, Vol.28 (5), p.1092-1100

2005

Volltextzugriff (PDF)

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea

Diabetes care, 2005-05, Vol.28 (5), p.1083-1091

2005

Volltextzugriff (PDF)

Membrane complement regulatory proteins

Clinical Immunology, 2006-02, Vol.118 (2), p.127-136

2006

Volltextzugriff (PDF)

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes

Diabetes care, 2004-11, Vol.27 (11), p.2628-2635

2004

Volltextzugriff (PDF)

Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option

American journal of hematology, 2021-02, Vol.96 (2), p.179-187

2021

Volltextzugriff (PDF)

Conversion of Intrathecal Opioids to Fentanyl in Chronic Pain Patients With Implantable Pain Pumps: A Retrospective Study

Neuromodulation (Malden, Mass.), 2019-10, Vol.22 (7), p.823-827

2019

Volltextzugriff (PDF)

Combined Orobol-Bentonite Composite Formulation for Effective Topical Skin Targeted Therapy in Mouse Model

International journal of nanomedicine, 2022-01, Vol.17, p.6513-6525

2022

Volltextzugriff (PDF)

Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data

European journal of haematology, 2024-02, Vol.112 (2), p.301-309

2024

Volltextzugriff (PDF)

Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation

Annals of hematology, 2020-06, Vol.99 (6), p.1377-1387

2020

Volltextzugriff (PDF)

Anti‐thymocyte globulin and post‐transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts

European journal of haematology, 2022-01, Vol.108 (1), p.61-72

2022

Volltextzugriff (PDF)

Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission

European journal of haematology, 2023-10, Vol.111 (4), p.553-561

2023

Volltextzugriff (PDF)

Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes

The journal of clinical endocrinology and metabolism, 2005-11, Vol.90 (11), p.5991-5997

2005

Volltextzugriff (PDF)

Poly((D,L)lactic-glycolic)acid-star glucose nanoparticles for glucose transporter and hypoglycemia-mediated tumor targeting

International journal of nanomedicine, 2017-01, Vol.12, p.7453-7467

2017

Volltextzugriff (PDF)

VA1 - Does the Timing of a Drug’s Costs and Benefits Influence us Payer Coverage of Special Drugs?

Value in health, 2018-05, Vol.21, p.S3-S3

2018

Volltextzugriff (PDF)

Does the Timing of a Drug’s Costs and Benefits Influence us Payer Coverage of Special Drugs?

Value in health, 2018-05, Vol.21, p.S3

2018

Volltextzugriff (PDF)

Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Acta haematologica, 2021-01, Vol.144 (1), p.66-73

2021

Volltextzugriff (PDF)

Anti‐thymocyte Globulin and Post‐Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen‐A and ‐B mismatched donors

European journal of haematology, 2022-04, Vol.108 (4), p.288-297

2022

Volltextzugriff (PDF)

Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR

European journal of haematology, 2021-09, Vol.107 (3), p.354-363

2021

Volltextzugriff (PDF)

Comparison of Outcomes After Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant Patients

Clinical lymphoma, myeloma and leukemia, 2022-05, Vol.22 (5), p.e327-e334

2022

Volltextzugriff (PDF)

Comparison of the Prognostic Ability of the HCT-CI, the Modified EBMT, and the EBMT-ADT Pre-transplant Risk Scores for Acute Leukemia

Clinical lymphoma, myeloma and leukemia, 2021-06, Vol.21 (6), p.e559-e568

2021

Volltextzugriff (PDF)

PHP212 - Comparing Cost-Per-Qalys Gained And Cost-Per-Dalys Averted Analyses

Value in health, 2018-05, Vol.21, p.S118-S118

2018

Volltextzugriff (PDF)

Comparing Cost-Per-Qalys Gained And Cost-Per-Dalys Averted Analyses

Value in health, 2018-05, Vol.21, p.S118

2018

Volltextzugriff (PDF)

Factors Predicting Restrictions on US Commercial Payer Coverage of Specialty Drugs

Value in health, 2018-05, Vol.21, p.S95

2018

Volltextzugriff (PDF)

1 – 25 von 642

Suche als RSS-Feed

Aktive Filter

ThemaRats

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(524)
Mit Volltextzugriff
(512)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(642)
Japanisch
(83)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus

Tumor Targeting and Lipid Rafts Disrupting Hyaluronic Acid-Cyclodextrin-Based Nanoassembled Structure for Cancer Therapy

Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea

Membrane complement regulatory proteins

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes

Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option

Conversion of Intrathecal Opioids to Fentanyl in Chronic Pain Patients With Implantable Pain Pumps: A Retrospective Study

Combined Orobol-Bentonite Composite Formulation for Effective Topical Skin Targeted Therapy in Mouse Model

Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data

Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation

Anti‐thymocyte globulin and post‐transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts

Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission

Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes

Poly((D,L)lactic-glycolic)acid-star glucose nanoparticles for glucose transporter and hypoglycemia-mediated tumor targeting

VA1 - Does the Timing of a Drug’s Costs and Benefits Influence us Payer Coverage of Special Drugs?

Does the Timing of a Drug’s Costs and Benefits Influence us Payer Coverage of Special Drugs?

Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Anti‐thymocyte Globulin and Post‐Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen‐A and ‐B mismatched donors

Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR

Comparison of Outcomes After Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant Patients

Comparison of the Prognostic Ability of the HCT-CI, the Modified EBMT, and the EBMT-ADT Pre-transplant Risk Scores for Acute Leukemia

PHP212 - Comparing Cost-Per-Qalys Gained And Cost-Per-Dalys Averted Analyses

Comparing Cost-Per-Qalys Gained And Cost-Per-Dalys Averted Analyses

Factors Predicting Restrictions on US Commercial Payer Coverage of Specialty Drugs

Aktive Filter

Suchergebnisse filtern